Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
POU domain, class 3, transcription factor 2 (POU3F2)
- Target
- POU3F2
- Molecular classification
- Transcription factor, POU domain family, DNA-binding protein
01
Overview
POU domain, class 3, transcription factor 2 (POU3F2, also known as BRN2 or N-Oct-3) is a neural transcription factor belonging to the POU homeobox family, characterized by binding to the octamer DNA sequence and regulating gene expression specifically in the central nervous system. POU3F2 plays an essential role in neuronal differentiation and development, acting as a transcriptional activator in cooperation with other neural-specific factors (ASCL1, SOX4, SOX11, SOX12, MYT1L). The protein has been associated with the development and proliferation of melanoma cells and is implicated in several neurodevelopmental and psychiatric disorders (including autism spectrum disorder, bipolar disorder, and syndromes of intellectual disability), as well as in CNS-specific gene regulation and neuronal reprogramming
- Other names
- BRN2N-Oct-3OTF7PO3F2POU3F2
02
Mechanism of action
Drugs or molecules targeting this protein would act via modulation of transcriptional activity—potentially altering neuronal differentiation, proliferation, or reprogramming, but specific drugs and mechanisms have not been detailed in current sources
03
Biological functions
Neuronal differentiationRegulation of gene expression in central nervous systemPromotion of neuronal gene transcriptionCellular proliferation (notably in melanoma)Reprogramming somatic cells to neurons (as part of a transcription factor combination with ASCL1 and MYT1L)
04
Disease associations
Autism spectrum disorderBipolar disorderObesity susceptibility with intellectual disability (chromosome 6q16.1 deletions)Cancer (especially melanoma proliferation)Microphthalmia
05
Safety considerations
Direct targeting of developmental transcription factors raises risks for off-target effects on neurogenesis and CNS functiontranscription factors are challenging as therapeutic targets due to potential for pleiotropic gene regulation
06
Interacting drugs
No direct drugs listed; POU3F2 itself is more commonly used as a research target in neuronal reprogramming and melanoma studies, rather than a current direct therapeutic target
07
Biomarkers
Rs1906252 SNP (linked to cognitive phenotype: information processing speed)deletion of chromosome 6q16.1 as a biomarker for intellectual disability and obesity susceptibility
Beyond the preview
Go deeper on POU domain, class 3, transcription factor 2 (POU3F2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on POU domain, class 3, transcription factor 2 (POU3F2).